Panelists discuss how the rapid adoption of subcutaneous (SubQ) oncology therapies creates challenges around clinical ...

Panelists discuss how switching from intravenous (IV) to subcutaneous (SubQ) therapies requires proactive management of reimbursement, authorizations, and clinical workflows—emphasizing early payer ...

BMS beats MSD to the US subcutaneous PD-1 inhibitor market after Opdivo Qvantiq is cleared across nearly all the indications of the IV form.

Patients receiving subcutaneous daratumumab have less chair time and premedication than those receiving IV formulation, says ...